Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by low blood counts and a propensity to develop acute myeloid leukemia. The management of lowerrisk (LR) MDS with persistent cytopenias remains suboptimal. Eltrombopag, a thrombopoietin-receptor agonist, can improv...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Vicente, Alana, Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Groarke, Emma M., Giudice, Valentina, Lotter, Jennifer, Feng, Xingmin, Kajigaya, Sachiko, Weinstein, Barbara, Barranta, Evette, Olnes, Matthew J., Parikh, Ankur R., Albitar, Maher, Wu, Colin O., Shalhoub, Ruba, Calvo, Katherine R., Townsley, Danielle M., Scheinberg, Phillip, Dunbar, Cynthia E., Young, Neal S., Winkler, Thomas
Format: Artigo
Language:Inglês
Published: Fondazione Ferrata Storti 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716353/
https://ncbi.nlm.nih.gov/pubmed/33256377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.249995
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items